Edgewise Debt To Equity from 2010 to 2025

EWTX Stock  USD 25.39  0.63  2.42%   
Edgewise Therapeutics Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2025. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.0153
Current Value
0.016
Quarterly Volatility
1.38797962
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 17.1 M, Interest Income of 17.1 M or Depreciation And Amortization of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.07. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Latest Edgewise Therapeutics' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Edgewise Therapeutics over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Edgewise Therapeutics' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.01 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Edgewise Debt To Equity Regression Statistics

Arithmetic Mean(1.79)
Coefficient Of Variation(77.62)
Mean Deviation1.13
Median(2.39)
Standard Deviation1.39
Sample Variance1.93
Range4.8109
R-Value0.61
Mean Square Error1.31
R-Squared0.37
Significance0.01
Slope0.18
Total Sum of Squares28.90

Edgewise Debt To Equity History

2025 0.016
2024 0.0153
2023 0.017
2021 0.0127
2020 -4.79

About Edgewise Therapeutics Financial Statements

Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.02  0.02 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.